Search

Your search keyword '"Goldberg RM"' showing total 491 results

Search Constraints

Start Over You searched for: Author "Goldberg RM" Remove constraint Author: "Goldberg RM"
491 results on '"Goldberg RM"'

Search Results

1. Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.

2. Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study

3. Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials

4. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer

5. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

6. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

7. Time course of regorafenib-associated adverse events in the phase III CORRECT study

8. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

9. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.

11. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.

12. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

14. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.

15. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

16. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.

18. Optimal delivery of cytotoxic chemotherapy for colon cancer.

19. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

21. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.

23. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

24. Cost implications of new treatments for advanced colorectal cancer.

25. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.

26. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

28. First-line therapeutic strategies in metastatic colorectal cancer.

37. Advances in the treatment of metastatic colorectal cancer.

39. Older Patients with Colon Cancer: Is Adjuvant Chemotherapy Safe and Effective?

40. Durable Responses to PD-1 Blockade in Mismatch-Repair Deficient Cancers, Independent of Tissue Origin

43. Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy.

44. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

45. Chemotherapy in the elderly.

46. Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer.

47. Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer.

48. Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.

49. Inflammation, Physical Activity, and Disease-Free Survival in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).

50. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.

Catalog

Books, media, physical & digital resources